Literature DB >> 10783778

Estimating data transformations in nonlinear mixed effects models.

A Oberg1, M Davidian.   

Abstract

A routine practice in the analysis of repeated measurement data is to represent individual responses by a mixed effects model on some transformed scale. For example, for pharmacokinetic, growth, and other data, both the response and the regression model are typically transformed to achieve approximate within-individual normality and constant variance on the new scale; however, the choice of transformation is often made subjectively or by default, with adoption of a standard choice such as the log. We propose a mixed effects framework based on the transform-both-sides model, where the transformation is represented by a monotone parametric function and is estimated from the data. For this model, we describe a practical fitting strategy based on approximation of the marginal likelihood. Inference is complicated by the fact that estimation of the transformation requires modification of the usual standard errors for estimators of fixed effects; however, we show that, under conditions relevant to common applications, this complication is asymptotically negligible, allowing straightforward implementation via standard software.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783778     DOI: 10.1111/j.0006-341x.2000.00065.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Bayesian multivariate hierarchical transformation models for ROC analysis.

Authors:  A James O'Malley; Kelly H Zou
Journal:  Stat Med       Date:  2006-02-15       Impact factor: 2.373

2.  Assessing nonlinearity in compartment models via the relative curvature measure.

Authors:  Takashi Daimon; Hiroshi Yamada; Masashi Goto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-12-07       Impact factor: 2.745

3.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

4.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

5.  The Box-Cox power transformation on nursing sensitive indicators: does it matter if structural effects are omitted during the estimation of the transformation parameter?

Authors:  Qingjiang Hou; Jonathan D Mahnken; Byron J Gajewski; Nancy Dunton
Journal:  BMC Med Res Methodol       Date:  2011-08-19       Impact factor: 4.615

6.  Mixed effects modeling of weight change associated with placebo and pregabalin administration.

Authors:  Bill Frame; Stuart L Beal; Raymond Miller; Jeannette Barrett; Paula Burger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-08-10       Impact factor: 2.410

7.  A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-17       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.